ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 88 filers reported holding ERASCA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,439 | -28.6% | 123,573 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $341,061 | -83.1% | 123,573 | -65.9% | 0.00% | -87.1% |
| Q2 2022 | $2,017,000 | -48.8% | 362,146 | -21.0% | 0.03% | -51.6% |
| Q1 2022 | $3,940,000 | -38.3% | 458,149 | +11.7% | 0.06% | -30.4% |
| Q4 2021 | $6,389,000 | -26.6% | 410,070 | -0.0% | 0.09% | -35.2% |
| Q3 2021 | $8,702,000 | – | 410,093 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 11,055,554 | $21,779,441 | 14.15% |
| EDBI Pte Ltd | 888,888 | $1,751,109 | 1.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 1,926,000 | $3,794,220 | 1.28% |
| Cormorant Asset Management, LP | 10,813,246 | $21,302,095 | 1.24% |
| AH Equity Partners LSV II, L.L.C. | 312,500 | $615,625 | 0.64% |
| Artal Group S.A. | 4,721,194 | $9,301 | 0.40% |
| PFM Health Sciences, LP | 3,930,633 | $7,743,347 | 0.36% |
| ARMISTICE CAPITAL, LLC | 8,356,000 | $16,461,320 | 0.25% |
| SANDERS MORRIS HARRIS LLC | 425,297 | $816,569 | 0.17% |
| Prosight Management, LP | 264,710 | $521,479 | 0.16% |